Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

"Amid Rising Private Labels and Digital-First Disruptors, the OTC Industry Faces a New Era of Competition. Explore Key Trends, Consumer Shifts, and Strategic Insights to Stay Ahead in a Rapidly ...

The "Ophthalmics Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of 344 ophthalmics ...

Minocycline hydrochloride capsule: Teva Pharmaceuticals has discontinued the 75 mg capsule presentation of minocycline hydrochloride, an antibiotic used for bacterial infections, for business reasons.

Teva Pharmaceuticals continues to beat consensus estimates, has once again raised its 2025 financial guidance and secured credit upgrades. Read more on why TEVA stock is a Buy.

Teva Pharmaceuticals' credit rating upgraded to BB+ by Fitch, reflecting debt reduction and positive growth outlook.

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today By Eric Volkman – May 12, 2025 at 5:02PM ...

A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries's (NYSE: TEVA) well higher on Monday. The company, known for being a top producer ...

Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30 ...